Publisher
Heighten Science Publications Corporation
Reference11 articles.
1. 1. Furst D, Keystone E, Braun J, Breedveld F, Burmester G, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis. 2011; 70: i2-36. Ref.: https://tinyurl.com/ydhu4qoy
2. 2. Davies R, Carrasco R, Foster H, Balidam E, Chieng S, et al. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective (CAPS). Semin Arthritis Rheum. 2016; 46: 190-195. Ref.: https://tinyurl.com/yayoxrsp
3. 3. Horneff G. Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opin Drug Saf. 2015; 14: 1111-1126. Ref.: https://tinyurl.com/y7s7dncp
4. 4. Hashkes P, Uziel Y, Laxer R. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol. 2010; 6: 561- 571. Ref.: https://tinyurl.com/y7ov3ckz
5. 5. Al-Mayouf S, Alenazi A, ALJasser H. Biologic agents therapy for Saudi children with rheumatic diseases: indications and safety. Int J Rheum Dis. 2016; 19: 600- 605. Ref.: https://tinyurl.com/ydgjmw76
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献